Is Oncosil Medical Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Oncosil Medical Ltd (OSL.AX) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Oncosil Medical Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Oncosil Medical Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Oncosil Medical Ltd?

Muslim investors may consider investing in Oncosil Medical Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Oncosil Medical Ltd classified as HALAL?

Musaffa determines the Shariah status of Oncosil Medical Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Oncosil Medical Ltd updated?

The Shariah compliance status of Oncosil Medical Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Oncosil Medical Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Oncosil Medical Ltd?

You can check the latest Shariah compliance status of Oncosil Medical Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

OSL.AX Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: July 29, 2025

Report Source: 2025 2nd Quarter Report

Analyst's Ratings for Oncosil Medical Ltd (OSL.AX)

Based on 7 analysts giving stock ratings to Oncosil Medical Ltd in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Oncosil Medical Ltd. Stock Analysis OSL.AX

Australia Health Care Nano Cap Report: Q2, 2025

OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in Macquarie, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The firm has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Key Statistics of Oncosil Medical Ltd (OSL.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.45AUD0.47

Today's Open

AUD0.45

Volume

41.16K

P/E Ratio (TTM)

52 Week Range

AUD0.45AUD2.09

Market Cap

15.81M

Avg. Volume

1313.40

Dividend Yield

Financial Metrics & Statements of Oncosil Medical Ltd (OSL.AX)

FAQ's for Oncosil Medical Ltd (OSL.AX)

According to Musaffa’s Shariah screening methodology, Oncosil Medical Ltd (OSL.AX) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.